When we explored the number of times pathways were hit pan-cancer, we found more hits to the three most affected pathways (TP53, RTK/KRAS, PI3K) by early mutations in metastatic cancer, relative to what was observed in primary cancer. This evidence concerns the gene KRAS and cancer.